BMY:NYE-Bristol-Myers Squibb Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 61.09

Change

0.00 (0.00)%

Market Cap

USD 109.38B

Volume

0.02B

Analyst Target

USD 73.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

N/A

USD 781.03B
JNJ Johnson & Johnson

N/A

USD 401.33B
NVO Novo Nordisk A/S

N/A

USD 393.39B
ABBV AbbVie Inc

N/A

USD 340.83B
PFE Pfizer Inc

N/A

USD 151.49B
OGN Organon & Co

N/A

USD 3.77B
GSK GlaxoSmithKline PLC ADR

N/A

N/A
MRK Merck & Company Inc

N/A

N/A
NVS Novartis AG ADR

N/A

N/A

ETFs Containing BMY

GF0F:XETRA Grayscale Future of Finan.. 7.49 % 0.00 %

N/A

N/A
CAMX Cambiar Aggressive Value .. 4.96 % 0.00 %

N/A

USD 0.06B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.55 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.49 % 0.00 %

N/A

N/A
MEDX Horizon Kinetics Medical .. 4.15 % 0.00 %

N/A

N/A
KNGU:CA Brompton U.S. Cash Flow K.. 4.11 % 0.00 %

N/A

CAD 0.01B
DIVP The Advisors’ Inner .. 3.61 % 0.00 %

N/A

USD 0.01B
HDCH:SW Invesco S&P 500 High Divi.. 3.09 % 0.00 %

N/A

USD 4.51M
ZYUS:AU ANZ S&P 500 High Yield Lo.. 3.07 % 0.00 %

N/A

USD 0.08B
MOTV:LSE VanEck Morningstar US Wid.. 3.02 % 0.00 %

N/A

USD 0.06B
CDNA:CA CI Bio-Revolution Index E.. 2.87 % 0.00 %

N/A

CAD 6.70M
MOTU:LSE VanEck Morningstar US Wid.. 2.82 % 0.00 %

N/A

USD 0.06B
MHOT:AU VanEck Morningstar Wide M.. 2.80 % 0.00 %

N/A

N/A
MOAT:AU VanEck Morningstar Wide M.. 2.80 % 0.00 %

N/A

USD 1.09B
HEAL:CA 2.66 % 0.00 %

N/A

N/A
MVFD Northern Lights Fund Trus.. 2.64 % 0.00 %

N/A

USD 0.07B
DHS:SW 2.39 % 0.00 %

N/A

N/A
DHSA:SW WisdomTree US Equity Inco.. 2.39 % 0.00 %

N/A

N/A
VDIV:F VanEck Vectors ETFs N.V... 2.34 % 0.00 %

N/A

USD 0.64B
TDIV:SW VanEck Morningstar Develo.. 2.34 % 0.00 %

N/A

USD 1.58B
VALQ American Century STOXX U... 2.31 % 0.29 %

N/A

USD 0.25B
XDGI:XETRA Xtrackers MSCI Global SDG.. 2.25 % 0.00 %

N/A

N/A
INCM:AU BetaShares Global Income .. 2.16 % 0.00 %

N/A

USD 0.03B
HEAL:SW iShares Healthcare Innova.. 2.00 % 0.00 %

N/A

USD 1.05B
PUD.B:CA 1.82 % 0.66 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 1.81 % 0.00 %

N/A

CAD 0.01B
UVDV 1.72 % 0.00 %

N/A

N/A
DIVG Invesco Exchange-Traded F.. 1.69 % 0.00 %

N/A

USD 3.14M
JAVA JPMorgan Active Value ETF 1.56 % 0.00 %

N/A

USD 2.82B
UC82:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

N/A

USD 0.03B
UC86:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

N/A

USD 0.25B
SPXB 1.32 % 0.15 %

N/A

N/A
UC98:LSE UBS(Lux)Fund Solutions .. 0.74 % 0.00 %

N/A

USD 0.13B
BSUS:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

N/A

N/A
UC97:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

N/A

USD 0.13B
UET0:F UBS (Lux) Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
UET0:XETRA UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
CBSUST:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
CBSUS:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
CBSUSE:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
CBSUSH:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
QUIG:CA Mackenzie US Investment G.. 0.62 % 0.28 %

N/A

CAD 0.58B
UC76:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

N/A

USD 0.08B
UC85:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

N/A

USD 0.12B
DHS WisdomTree U.S. High Divi.. 0.00 % 0.38 %

N/A

N/A
GBF iShares Government/Credit.. 0.00 % 0.20 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
ONEV SPDR® Russell 1000 Low V.. 0.00 % 0.20 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

N/A
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

N/A

USD 1.71B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

N/A

USD 0.41B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD 0.02B
HONR 0.00 % 0.65 %

N/A

N/A
HUL-U:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
SCHD Schwab U.S. Dividend Equi.. 0.00 % 0.07 %

N/A

USD 68.08B
SICK 0.00 % 0.95 %

N/A

N/A
UXM.B:CA 0.00 % 0.67 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.22B
HUL:CA 0.00 % 2.20 %

N/A

N/A
BVAL 0.00 % 0.65 %

N/A

N/A
DHS:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSA:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSD:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSG:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
DHSP:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

N/A

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

N/A
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

N/A

USD 0.08B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 0.01B
MVUS:PA 0.00 % 0.00 %

N/A

N/A
SPMV:PA 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

N/A

N/A
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 0.00 % 0.00 %

N/A

USD 0.13B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

N/A
VDIV:XETRA VanEck Morningstar Develo.. 0.00 % 0.00 %

N/A

N/A
VMUS:XETRA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
REVS Columbia Research Enhance.. 0.00 % 0.00 %

N/A

USD 0.07B
AGNG Global X Aging Population.. 0.00 % 0.00 %

N/A

USD 0.06B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

CAD 0.08B
DAVV:F VanEck Crypto and Blockch.. 0.00 % 0.00 %

N/A

N/A
DAVV:XETRA VanEck Crypto and Blockch.. 0.00 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.01% 50% F 86% B+
Dividend Return 1.10% 57% F 59% D-
Total Return 9.11% 50% F 87% B+
Trailing 12 Months  
Capital Gain 13.57% 70% C- 78% C+
Dividend Return 4.50% 78% C+ 67% D+
Total Return 18.07% 90% A- 81% B-
Trailing 5 Years  
Capital Gain 5.45% 22% F 41% F
Dividend Return 18.59% 67% D+ 54% F
Total Return 24.05% 22% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -2.22% 30% F 22% F
Dividend Return 1.04% 30% F 26% F
Total Return 3.25% 60% D- 66% D+
Risk Return Profile  
Volatility (Standard Deviation) 19.51% 50% F 55% F
Risk Adjusted Return 5.33% 30% F 24% F
Market Capitalization 109.38B 29% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.